The relationship between CMV reactivation, anti-cytokine treatment and mortality in critical COVID-19 patients

Basit Öğe Kaydı
dc.authoridRamazan Gözüküçük / 0000-0002-8205-4752
dc.contributor.authorGözüküçük, Ramazan
dc.contributor.authorKılıç, Hasan Hüseyin
dc.date.accessioned2023-10-04T09:02:31Z
dc.date.available2023-10-04T09:02:31Z
dc.date.issued2023
dc.departmentFakülteler, Diş Hekimliği Fakültesi, Temel Bilimler Bölümü
dc.description.abstractObjective: To examine the use of anti-cytokine treatment in critical COVID-19 patients and their association with the frequency of CMV cases, viral load level, and mortality in these patients. Methods: This is a retrospective study. A total of 170 critical and/or intensive care patients with COVID-19 admitted to Hisar Hospital Intercontinental from March 15, 2020, to December 31, 2021 were divided into the use of anti-cytokine treatment group and the no anti-cytokine treatment group. Furthermore, the relationship between CMV reactivation, mortality and anti-cytokine treatment in patients was also examined. Results: A total of 170 critical COVID-19 patients were included in the study, three of them were excluded. One hundred sixty seven were included in the study of which 38 (22.7%) were found to be CMV DNA positive. As an anti-cytokine treatment, it was observed that tocilizumab was used in 53 patients, anakinra was used in 27 patients, and no anti-cytokine treatment was used in 77 patients. CMV positivity in patients treated with anti-cytokines (31.11%) was found to be significantly higher than in patients who were not treated with it (16.88%) (p:0.033). Furthermore, it was determined that anti-cytokine treatment significantly decreased mortality (p: 0.003) and that there was no significant relationship between CMV reactivation and mortality (p: 0.399). Conclusion: Even though CMV reactivation was high in critical COVID-19 patients who received anti-cytokine treatment, decrease in mortality were observed with early diagnosis and effective treatment. Therefore, CMV infection should be considered in patients receiving immunosuppressive treatment.Clinical Trial Registration: HisarIH-101/NCT05419206.
dc.identifier.citationRamazan Gözüküçük, & Hasan Kılıç. (2023). The relationship between CMV reactivation, anti-cytokine treatment and mortality in critical COVID-19 patients. Pakistan Journal of Medical Sciences, 39(5). https://doi.org/10.12669/pjms.39.5.7301‌en_US
dc.identifier.doi10.12669/pjms.39.5.7301
dc.identifier.endpage1290
dc.identifier.issn1682-024X
dc.identifier.issn1681-715X
dc.identifier.issue5
dc.identifier.startpage1286
dc.identifier.urihttp://dx.doi.org/10.12669/pjms.39.5.7301
dc.identifier.urihttps://hdl.handle.net/20.500.12941/154
dc.identifier.volume39
dc.identifier.wosWOS:001076504500011
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthorGözüküçük, Ramazan
dc.language.isoen
dc.relation.ispartofPak J Med Sci
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTocilizumab
dc.subjectAnakinra
dc.subjectAnti-cytokine treatment
dc.subjectMortality
dc.subjectCytomegalovirus (CMV)
dc.subjectCOVID-19
dc.titleThe relationship between CMV reactivation, anti-cytokine treatment and mortality in critical COVID-19 patients
dc.typeArticle

Dosyalar

Koleksiyon

Temel Bilimler Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu